Glenmark Pharmaceuticals Ltd on Wednesday announced a licensing deal with Chinese drugmaker Hengrui Pharma for its under-development lung and breast cancer drug. The deal involves an upfront payment of $18 million, followed by regulatory and commercial milestone payments of up to $1.093 billion, as well as royalties.Glenmark Specialty S.A., a wholly-owned subsidiary of the Mumbai-based drugmaker, signed the exclusive license and collaboration agreement with Hengrui for its drug, Trastuzumab Rezetecan (SHR-A ...